R43TR004975
Project Grant
Overview
Grant Description
Device automation of an FDA-cleared CD-microfluidic platform for rapid tissue microsizing - abstract
There is a need in the market for a true platform technology that automates the tissue processing experience. Syntr Health Technologies has dedicated the last six years developing the technology that can streamline tissue processing. Our FDA-cleared Syntrfuge system and Syntrfpu360, is a platform technology that can process a variety of different tissue types such as cancer tumors of kidney, liver, brain, and breast tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, of which the single cell analysis market is valued at $3.3 billion and expected to grow to $6.3 billion by 2026.
As well, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers and knee osteoarthritis. Syntr has successfully completed an SBIR phase I grant where we utilized micronized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that translated successfully into humans.
Preliminary human clinical data is showing significant diabetic foot ulcer wound closure within 3- 5 weeks using autologous adipose tissue processed in our platform. The diabetic foot ulcer market is currently valued at $1.98 billion with a CAGR of 8.2%. This high growth potential is attributed to the increase of the diabetic population. Additionally, the use of microsized adipose tissue is showing great promise in intra-articular injections to knee joints for the treatment of osteoarthritis (OA).
The knee OA market in North America is currently valued at $5.9 billion and growing at a CAGR of 8.8%. Over 88% of individuals with OA are 45 or older. The high growth potential of this market is largely attributed to the increase of the aging population along with the increase in obesity rates. Our platform technology for the rapid processing and/or microsizing of tissues can disrupt these markets in a major way. The automation of this technology in this phase I SBIR is paramount to increase favorability in the adoption of this much needed technology in various medical fields.
There is a need in the market for a true platform technology that automates the tissue processing experience. Syntr Health Technologies has dedicated the last six years developing the technology that can streamline tissue processing. Our FDA-cleared Syntrfuge system and Syntrfpu360, is a platform technology that can process a variety of different tissue types such as cancer tumors of kidney, liver, brain, and breast tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, of which the single cell analysis market is valued at $3.3 billion and expected to grow to $6.3 billion by 2026.
As well, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers and knee osteoarthritis. Syntr has successfully completed an SBIR phase I grant where we utilized micronized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that translated successfully into humans.
Preliminary human clinical data is showing significant diabetic foot ulcer wound closure within 3- 5 weeks using autologous adipose tissue processed in our platform. The diabetic foot ulcer market is currently valued at $1.98 billion with a CAGR of 8.2%. This high growth potential is attributed to the increase of the diabetic population. Additionally, the use of microsized adipose tissue is showing great promise in intra-articular injections to knee joints for the treatment of osteoarthritis (OA).
The knee OA market in North America is currently valued at $5.9 billion and growing at a CAGR of 8.8%. Over 88% of individuals with OA are 45 or older. The high growth potential of this market is largely attributed to the increase of the aging population along with the increase in obesity rates. Our platform technology for the rapid processing and/or microsizing of tissues can disrupt these markets in a major way. The automation of this technology in this phase I SBIR is paramount to increase favorability in the adoption of this much needed technology in various medical fields.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
California
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 44% from $306,161 to $441,060.
Syntr Health Technologies was awarded
Project Grant R43TR004975
worth $441,060
from National Center for Advancing Translational Sciences in December 2023 with work to be completed primarily in California United States.
The grant
has a duration of 1 year and
was awarded through assistance program 93.350 National Center for Advancing Translational Sciences.
The Project Grant was awarded through grant opportunity PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed).
SBIR Details
Research Type
SBIR Phase I
Title
Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing
Abstract
ABSTRACT There is a need in the market for a true platform technology that automates the tissue processing experience. Syntr Health Technologies has dedicated the last six years developing the technology that can streamline tissue processing. Our FDA-cleared SyntrFuge System and SyntrFPU360, is a platform technology that can process a variety of different tissue types such as cancer tumors of kidney, liver, brain, and breast tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, of which the single cell analysis market is valued at $3.3 Billion and expected to grow to $6.3 Billion by 2026. As well, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers and knee osteoarthritis. Syntr has successfully completed an SBIR Phase I grant where we utilized micronized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that translated successfully into humans. Preliminary human clinical data is showing significant diabetic foot ulcer wound closure within 3- 5 weeks using autologous adipose tissue processed in our platform. The diabetic foot ulcer market is currently valued at $1.98 Billion with a CAGR of 8.2%. This high growth potential is attributed to the increase of the diabetic population. Additionally, the use of microsized adipose tissue is showing great promise in intra-articular injections to knee joints for the treatment of osteoarthritis (OA). The knee OA market in North America is currently valued at $5.9 Billion and growing at t CAGR of 8.8%. Over 88% of individuals with OA are 45 or older. The high growth potential of this market is largely attributed to the increase of the aging population along with the increase in obesity rates. Our platform technology for the rapid processing and/or microsizing of tissues can disrupt these markets in a major way. The automation of this technology in this Phase I SBIR is paramount to increase favorability in the adoption of this much needed technology in various medical fields..
Topic Code
NCATS
Solicitation Number
PA21-345
Status
(Complete)
Last Modified 4/4/25
Period of Performance
12/15/23
Start Date
12/14/24
End Date
Funding Split
$441.1K
Federal Obligation
$0.0
Non-Federal Obligation
$441.1K
Total Obligated
Activity Timeline
Transaction History
Modifications to R43TR004975
Additional Detail
Award ID FAIN
R43TR004975
SAI Number
R43TR004975-1916327483
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75NR00 NIH National Center for Advancing Translational Sciences
Funding Office
75NR00 NIH National Center for Advancing Translational Sciences
Awardee UEI
DTC9T712PUB3
Awardee CAGE
7P2D8
Performance District
CA-90
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 4/4/25